Regeneron-Sanofi Partnership Quietly Reshapes Stock Story

While investors fixate on Regeneron Pharmaceuticals' (REGN) pipeline, a powerful and accelerating profit stream from its collaboration with Sanofi is quietly reshaping the company's financial core, according to a report from Trefis.

Partnership Details

Regeneron and Sanofi collaborate on several successful drugs, including Dupixent for inflammatory diseases. The agreement allows Regeneron to receive a share of sales profits, which have grown significantly as Dupixent's indications expand.

Financial Impact

Reports indicate that partnership revenues are becoming an increasingly large portion of Regeneron's profits, reducing reliance on its internal pipeline and providing financial stability. This strong cash flow could support the company's R&D investments and share buybacks.

What It Means for Investors

Although the focus is often on new drugs in development, the strength of the Sanofi partnership offers a different perspective on Regeneron's value. Investors may need to reassess the company's business model considering this growing profit source.